Analysts' recommendations: Alzinova AB

06-24	RX Securities reiterates buy on Alzinova after letter of intent with Fujirebio	FW
04-08	RX Securities sees potential upside for Alzinova from Alzheimer's diagnostic collaboration	FW
03-26	DNB Carnegie sees reduced financing risk for Alzinova, but partnership remains critical	FW
06/10/25	Alzinova gets fast track designation from US FDA	RE
06/10/25	Alzinova's Alzheimer's Disease Vaccine Candidate Gets Fast-track Designation from US FDA	MT

More recommendations

Managers and Directors: Alzinova AB

Manager	Title	Age	Since
Tord Labuda CEO	Chief Executive Officer	59	30/09/2024
Anders Sandberg COO	Chief Operating Officer	54	16/08/2011
Erik Kullgren DFI	Director of Finance/CFO	57	26/03/2024

Director	Title	Age	Since
Anders Waas BRD	Director/Board Member	69	31/12/2017
Per-Göran Gillberg BRD	Director/Board Member	70	31/12/2019
Julian Aleksov CHM	Chairman	61	31/12/2022

More insiders

Other Biotechnology & Medical Research

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ALZINOVA AB	+0.55%	+9.22%	-65.42%	-82.42%	8.65M
LONZA GROUP AG	-0.58%	+7.04%	-5.22%	+2.30%	46.36B
REVOLUTION MEDICINES, INC.	+4.95%	+9.31%	+363.86%	+598.16%	37.88B
IQVIA HOLDINGS INC.	+0.44%	+11.12%	+17.47%	-12.91%	31.12B
BEONE MEDICINES AG	-0.64%	+1.92%	+3.08%	+53.58%	30.61B
CELLTRION, INC.	+0.23%	-0.29%	+13.24%	+21.10%	24.69B
ASCENDIS PHARMA A/S	+9.90%	+13.32%	-	-	16.25B
MEDPACE HOLDINGS, INC.	+1.40%	+12.99%	+67.11%	+132.76%	14.85B
EUROFINS SCIENTIFIC SE	-0.06%	+9.18%	+12.16%	+21.59%	13.58B
IONIS PHARMACEUTICALS, INC.	+2.38%	+5.69%	+95.85%	+97.63%	12.95B
Average	+1.86%	+8.69%	+55.79%	+92.42%	22.83B
Weighted average by Cap.	+1.63%	+8.01%	+79.73%	+132.29%

See all sector performances

Alzinova AB is a Sweden-based company, which is primarily involved in the biotechnology industry. The Company is engaged in the discovery and development of therapeutics for the treatment of Alzheimerâ€™s disease. The Company focuses on development of a specific oligomer-directed vaccine (ALZ-101), as well as on the development of diagnostics based on a monoclonal antibody (ALZ-201). Both products are specifically directed towards the form of oligomeric AÎ² that damages brain synapses.

Employees

Sector

Biotechnology & Medical Research

Calendar

Earnings release - Q2 2026

More about the company

Quotes

Date	Price	Change	Volume
26/06/26	SEK 0.5450	+0.55%	507,651
25/06/26	SEK 0.5420	+2.26%	1,308,817
24/06/26	SEK 0.5300	+8.72%	3,545,500
23/06/26	SEK 0.4875	-2.30%	207,925
22/06/26	SEK 0.4990	+4.07%	1,042,878

Delayed Quote Nasdaq Stockholm

More quotes

Income Statement and Estimates

More financial data

EPS Estimates

Revisions to estimates

Annual profits - Rate of surprise

Company calendar

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

Delayed Nasdaq Stockholm Other stock markets 10:58:25 26/06/2026 BST			5-day change	1st Jan Change
0.5450 ^SEK	+0.55%		+9.22%	-34.26%

Market Cap	83.99M 8.65M 7.6M 7M 6.55M 12.28M 816M 12.5M 32.53M 402M 32.48M 31.77M 1.4B	P/E 2026 *	-2.01x	P/E 2027 *	-1.43x
Enterprise Value	67.99M 7M 6.15M 5.67M 5.3M 9.94M 661M 10.12M 26.33M 326M 26.29M 25.72M 1.13B	EV / Sales 2026 *	2.17x	EV / Sales 2027 *	-
Free-Float	82.23%	Yield 2026 *	-	Yield 2027 *	-

06-24	Alzinova AB and Fujirebio Enter Letter of Intent for Potential Commercialization of Blood-Based Alzheimer?S Diagnostic Test	CI
06-24	Alzinova Inks Nonbinding Deal with Fujirebio for Potential Alzheimer's Blood-based Diagnostic Test	MT
06-24	RX Securities reiterates buy on Alzinova after letter of intent with Fujirebio	FW
06-24	Alzinova signs non-binding letter of intent with Fujirebio on Alzheimer's diagnostics	FW
06-12	Alzinova raises SEK15.3m from warrants: underwriting not required	FW
06-08	Alzinova raises SEK 15.2 million before issuance costs	FW
05-26	Calendar Tuesday May 26	FW
05-25	Calendar Tuesday May 26	FW
05-21	Alzinova secures 80 percent of TO4 warrants	FW
05-20	Alzinova phase 1b results published in scientific journal	FW
05-20	Alzinova AB Publishes Clinical Results with ALZ-101 in Alzheimer?s Research & Therapy	CI
05-13	Alzinova AB Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-13	Alzinova Q1 loss after financial items SEK 6 mln	RE

06-24	Alzinova: Newsflow update – diagnostic optionality and TO4 proceeds	AQ
06-24	Alzinova signs Letter of Intent with Fujirebio regarding potential commercialization of blood-based Alzheimer’s diagnostic test	AQ
06-12	Warrants of series TO4 were exercised to approximately 94.2 percent and the Company will receive approximately 15.3 million	AQ
06-08	Alzinova announces preliminary outcome of the exercise of warrants of series TO4	AQ
06-03	The last day of trading with the warrants of series TO4 in Alzinova is today, June 3, 2026	AQ

1 day	+0.55%
1 week	+9.22%
Current month	+26.60%
1 month	+17.20%
3 months	-7.47%
6 months	-31.88%
Current year	-34.26%

Alzinova AB Share Price

Stocks

ALZ

SE0007413455

Biotechnology & Medical Research

Valuation: Alzinova AB

Chart: Alzinova AB

Latest news : Alzinova AB

Analysts' recommendations: Alzinova AB

Press Releases: Alzinova AB

Quotes and Performance

Course Extremes

Managers and Directors: Alzinova AB

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

Annual profits - Rate of surprise

1 week	0.46	0.59
1 month	0.41	0.59
Current year	0.38	0.97
1 year	0.38	2.28
3 years	0.38	4.62
5 years	0.38	9.18
10 years	0.38	44.9

	2026 *	2027 *
Net sales	31.35M 3.23M 2.84M 2.61M 2.44M 4.58M 305M 4.67M 12.14M 150M 12.12M 11.86M 522M	-
Net income	-3.2M -330K -289K -267K -249K -468K -31.1M -476K -1.24M -15.33M -1.24M -1.21M -53.27M	-50.35M -5.19M -4.55M -4.2M -3.92M -7.36M -489M -7.49M -19.5M -241M -19.47M -19.05M -838M
Net Debt	-16M -1.65M -1.45M -1.33M -1.25M -2.34M -155M -2.38M -6.2M -76.64M -6.19M -6.05M -266M	-19M -1.96M -1.72M -1.58M -1.48M -2.78M -185M -2.83M -7.36M -91.02M -7.35M -7.19M -316M